SAN FRANCISCO (Thomson Financial) - Abbott Laboratories Inc. said Friday it has received Food and Drug Administration approval for its cholesterol treatment Simcor.
Simcor combines Abbott's proprietary niacin extended-release Niaspan and simvastatin.
The drug is approved to treat, along with diet, elevated total cholesterol, LDL cholesterol and triglycerides, and to raise HDL cholesterol in patients with complex lipid disease when treatment with simvastatin or Niaspan monotherapies are not considered adequate, Abbott said.
The FDA's approval was based on Simcor safety and efficacy trial data from more than 640 patients with mixed dyslipidemia and type II hyperlipidemia, the Abbott Park, Ill.-based health care company said.
Abbott shares were up 17 cents at $55.55 at the closing bell. Brigid Gaffikin bg/tk1 COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
© 2008 AFX News
